PL376509A1 - Antagoniści IL-15 - Google Patents
Antagoniści IL-15Info
- Publication number
- PL376509A1 PL376509A1 PL03376509A PL37650903A PL376509A1 PL 376509 A1 PL376509 A1 PL 376509A1 PL 03376509 A PL03376509 A PL 03376509A PL 37650903 A PL37650903 A PL 37650903A PL 376509 A1 PL376509 A1 PL 376509A1
- Authority
- PL
- Poland
- Prior art keywords
- antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02022869 | 2002-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL376509A1 true PL376509A1 (pl) | 2005-12-27 |
Family
ID=32103882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03376509A PL376509A1 (pl) | 2002-10-14 | 2003-10-13 | Antagoniści IL-15 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060236411A1 (pl) |
| EP (1) | EP1554307A2 (pl) |
| JP (1) | JP2006518583A (pl) |
| KR (1) | KR20050049545A (pl) |
| CN (1) | CN1703423A (pl) |
| AU (1) | AU2003269659A1 (pl) |
| BR (1) | BR0315327A (pl) |
| CA (1) | CA2502316A1 (pl) |
| MX (1) | MXPA05003887A (pl) |
| PL (1) | PL376509A1 (pl) |
| RU (1) | RU2005114526A (pl) |
| WO (1) | WO2004035622A2 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
| CN100334112C (zh) * | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CN101831435B (zh) * | 2010-05-10 | 2013-09-11 | 昆山贝瑞康生物科技有限公司 | 小鼠il-15亚型蛋白的制备及其应用 |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| ES2778053T3 (es) * | 2011-01-18 | 2020-08-07 | Bioniz Llc | Composiciones para modular la actividad de la citocina gamma-c |
| JP6292718B2 (ja) | 2011-07-01 | 2018-03-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝集ポリペプチドから単量体ポリペプチドを分離するための方法 |
| KR102539359B1 (ko) | 2013-04-19 | 2023-06-02 | 싸이튠 파마 | 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료 |
| ES2698375T3 (es) | 2013-06-27 | 2019-02-04 | Inst Nat Sante Rech Med | Antagonistas de interleucina 15 (IL-15) y usos de los mismos para el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| LT3235830T (lt) * | 2014-12-19 | 2020-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukino 15 baltymų kompleksas ir jo naudojimas |
| EP3359556B1 (en) | 2015-10-09 | 2021-05-26 | Bioniz, LLC | Modulating gamma - c -cytokine activity |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| KR20240142577A (ko) | 2017-04-07 | 2024-09-30 | 바이오니즈 테라퓨틱스, 아이엔씨. | 감마-c-사이토카인 활성의 안정한 조절자 |
| US12060577B2 (en) * | 2017-05-19 | 2024-08-13 | Case Western Reserve University | Compositions for expanding natural killer cells |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| WO2019222294A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CA3102821A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| US11952419B2 (en) * | 2018-07-10 | 2024-04-09 | University Of Connecticut | Reagents and methods for treating cancer and autoimmune disease |
| CN112534052B (zh) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | 全新il-21前药及使用方法 |
| MX2021003543A (es) | 2018-09-27 | 2021-06-23 | Xilio Dev Inc | Polipeptidos de citocinas enmascaradas. |
| JP2022530677A (ja) | 2019-05-03 | 2022-06-30 | バイオニズ リミテッド ライアビリティー カンパニー | 脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| JP7807076B2 (ja) * | 2019-12-13 | 2026-01-27 | キュージーン インコーポレイテッド | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| JP7767290B2 (ja) | 2020-01-11 | 2025-11-11 | アスクジーン・ファーマ・インコーポレイテッド | 新規なマスクされたサイトカインおよびその使用方法 |
| JP2023553323A (ja) | 2020-11-25 | 2023-12-21 | エクシリオ デベロップメント， インコーポレイテッド | 腫瘍特異的に切断可能なリンカー |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5698765A (en) * | 1991-12-02 | 1997-12-16 | The Ontario Cancer Institute | Mouse having a disrupted CD4 gene |
| WO1993018144A1 (en) * | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
| US5625122A (en) * | 1992-04-24 | 1997-04-29 | The Ontario Cancer Institute | Mouse having a disrupted lck gene |
| JP3741447B2 (ja) * | 1992-10-23 | 2006-02-01 | 中外製薬株式会社 | エンドセリン−１遺伝子の機能が欠損したマウス |
| EP1621206A1 (en) * | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| US6001973A (en) * | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
-
2003
- 2003-10-13 US US10/530,987 patent/US20060236411A1/en not_active Abandoned
- 2003-10-13 BR BR0315327-4A patent/BR0315327A/pt not_active IP Right Cessation
- 2003-10-13 JP JP2004543889A patent/JP2006518583A/ja active Pending
- 2003-10-13 PL PL03376509A patent/PL376509A1/pl not_active Application Discontinuation
- 2003-10-13 AU AU2003269659A patent/AU2003269659A1/en not_active Abandoned
- 2003-10-13 MX MXPA05003887A patent/MXPA05003887A/es unknown
- 2003-10-13 CA CA002502316A patent/CA2502316A1/en not_active Abandoned
- 2003-10-13 KR KR1020057006381A patent/KR20050049545A/ko not_active Withdrawn
- 2003-10-13 RU RU2005114526/13A patent/RU2005114526A/ru not_active Application Discontinuation
- 2003-10-13 WO PCT/CH2003/000666 patent/WO2004035622A2/de not_active Ceased
- 2003-10-13 CN CNA2003801013333A patent/CN1703423A/zh active Pending
- 2003-10-13 EP EP03750224A patent/EP1554307A2/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004035622A2 (de) | 2004-04-29 |
| CA2502316A1 (en) | 2004-04-29 |
| MXPA05003887A (es) | 2005-10-18 |
| RU2005114526A (ru) | 2005-10-10 |
| CN1703423A (zh) | 2005-11-30 |
| KR20050049545A (ko) | 2005-05-25 |
| AU2003269659A1 (en) | 2004-05-04 |
| US20060236411A1 (en) | 2006-10-19 |
| JP2006518583A (ja) | 2006-08-17 |
| EP1554307A2 (de) | 2005-07-20 |
| BR0315327A (pt) | 2005-08-16 |
| WO2004035622A3 (de) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165841A0 (en) | Mchir antagonists | |
| IL166084A0 (en) | Novel benzodioxoles | |
| PL371678A1 (pl) | Nowe pochodne pirydyny i pirymidyny | |
| PL373598A1 (pl) | Nowe benzonaftyrydyny | |
| GB0206048D0 (en) | Use | |
| IL163652A0 (en) | Substituted hydroxyethylamines | |
| PL372804A1 (pl) | Wibrator | |
| GB0211257D0 (en) | Novel heterocycles | |
| IL163529A0 (en) | Novel spinosyn-producing polyketidesynthases | |
| IL163939A0 (en) | Nk1 antagonists | |
| SI1487778T1 (sl) | Substituirani 4-aminocikloheksanoli | |
| IL164975A0 (en) | Novel combination | |
| GB0226227D0 (en) | Receptors | |
| IL166740A0 (en) | Substituted heterocyclylpyrimidines | |
| GB0214784D0 (en) | Novel combination | |
| GB0209989D0 (en) | Novel heterocycles | |
| AU152494S (en) | Level | |
| GB0223399D0 (en) | Receptors | |
| PL377325A1 (pl) | Podstawione benzodioksepiny | |
| GB0204720D0 (en) | Novel use | |
| GB0210682D0 (en) | Novel use | |
| GB0229743D0 (en) | Novel benzoxazocines | |
| GB0209988D0 (en) | Novel Heterocycles | |
| IL147930A0 (en) | Vibrator | |
| GB0228112D0 (en) | Receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |